Would You Add These To Your Penny Stocks To Buy Or Sell List?
Just like Santa has a naughty or nice list, traders have a penny stocks to buy or sell list. Or, at the very least a “penny stocks to buy or avoid” list. No matter what you label it, the idea of creating a list of penny stocks is great. Being an organized trader is just as important as understanding how to read a filing or assess a news release.
This year’s climate for cheap stocks has been very hot. Volatility in the larger cap markets has translated to more momentum for small-caps. So more people are becoming familiar with what penny stocks really are. Are these risky equities? Yes, of course, they are. When you deal with low priced stocks, a small move is great if it goes in the right direction. But obviously a move in the opposite direction means you could lose your entire investment.
But at the end of the day, no risk means no reward and in the stock market, there are plenty of both. If you’re able to find the right penny stocks to buy, you can find yourself making quick money in the stock market. It all starts with a list, so you be the judge, are these stocks to buy or avoid before the new year?
Penny Stocks To Buy [or avoid] #4: BioPharmX Corporation (BPMX)
First, on this list of penny stocks, BioPharmX Corporation (BPMX Stock Report) has enjoyed a great trend these last few weeks. Back in late November, shares were trading around $0.27 per share. They’ve since sprung to highs of $0.433 this week.
What’s helped fuel this 60+% rally? Tough to say right now. The last update from the company came with bad news. BioPharmX received notice of compliance deadline extension from the NYSE to meet the requirements of the exchange by March 24 of next year. Aside from that, there are corporate earnings to take a look at if/when they are released.
- These Penny Stocks Are Up Big In December; Can They Head Higher?
- Are These Penny Stocks To Buy Or Sell Right Now? 1 Up 100% This Week
Also, from its September 20th announcement, we still need to see if BPMX can deliver on the statement made by Dr. Tierney, BioPharmX CEO, “Our goal is to announce a strategic partnership transaction to advance our late-stage topical minocycline drug candidates in Q4 2019.”
Penny Stocks To Buy [or avoid] #3: Sunesis Pharmaceuticals (SNSS)
One of the penny stocks that hit new 52-week lows this month was Sunesis Pharmaceuticals (SNSS Stock Report). But that’s not where the story ends. Since hitting those lows today, SNSS stock rallied back to close near its high of the day at $0.3793. What cause this penny stock to drop and pop?
It’s not frequent that you see mid-morning news released after the open with penny stocks. However, after a massive sell-off at the opening bell, Sunesis rallied strongly. This came on the back of new data from its Phase 1b/2 clinical trials. The data comes from tests of its BTK inhibitor vecabrutinib in adults with specific types of leukemia. The company will also present data Sunday at the American Society of Hematology Annual Meeting. Needless to say, the preliminary results were well received by the market.
“The data are encouraging, with vecabrutinib showing evidence of clinical activity in high-risk patients resistant to covalent BTK inhibitors, in both wild-type and C481-mutated BTK disease,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “Vecabrutinib is very well tolerated at the dose levels studied thus far, with patients now being treated in the 400 mg cohort. We are prepared for Phase 2 expansion, which will focus on BTK inhibitor-resistant CLL/SLL patients and those with prior intolerance to other BTK inhibitors.”
Penny Stocks To Buy [or avoid] #2: Matinas BioPharma (MTNB)
Another one of the penny stocks that’s exploded within the last few months was Matina BioPharma (MTNB Stock Report). Shares have skyrocketed since late September after announcing favorable data from a Phase 2 ENHANCE-IT study versus Vascepa. Thanks to an FDA win by Amarin Corp (AMRN) for its Vascepa treatment, Matinas enjoyed similar sentiment for its own drug.
“Our second head-to-head trial against Vascepa is an important milestone for our Company, and pre-screening patients for eligibility will facilitate rapid enrollment in the first quarter of 2020,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. “Topline data from this study, which we expect in the second half of 2020, will be another opportunity to distinguish MAT9001 from the market-leading therapy in this emerging prescription omega-3 space.”
The company had also begun another study for its MAT2203 for induction and maintenance therapy in HIV-patients with certain illnesses. This week the company presented at the Piper Jaffray Healthcare Conference. Based on the momentum in the market, it appears things were well-received. With all of these big developments, will MTNB remain a penny stock to buy? Or should you avoid it after it made new 52-week highs this week? Well, year-to-date, MTNB stock has rallied as much as 177% after those new highs.
Penny Stocks To Buy [or avoid] #1: Nautilus (NLS)
Have you ever worked out on a Nautilus (NLS Stock Report)? Well, come to find out, it too is a penny stock. I won’t get into how the term penny stock doesn’t always refer to a start-up company. Or the fact that some well-known brands trade publicly as penny stocks. But I will talk about how NLS stock has rallied this month. Since December 2, Nautilus stock has moved from $1.46 to highs of $1.89 in after-hours trading on Thursday.
Its Octane Trifecta has received a lot of attention heading into the holiday season. It includes a rower, bike, and cross-training machine. “We are thrilled to fuel growing participation in indoor rowing with the exceptional design and performance of the unique Rō,” said Jim Barr, CEO of Nautilus, Inc.
“And the powerful Octane Trifecta is a one-stop-shop, so fitness centers can meet the demand for functional training, and potentially boost revenue and retention, with a collection of intuitive, challenging and compact exercise equipment.”
Aside from that, there haven’t been any press releases in December. There haven’t been any corporate fillings either. Assuming positive sentiment has echoed from companies like Peloton (PTON Stock Report) and other fitness brands, will it be a happy holiday for Nautilus?